SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 96.94 |
| Enterprise Value ($M) | 73.30 |
| Book Value ($M) | 126.80 |
| Book Value / Share | 1.28 |
| Price / Book | 0.76 |
| NCAV ($M) | 83.31 |
| NCAV / Share | 0.84 |
| Price / NCAV | 1.16 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.70 |
| Return on Assets (ROA) | -0.19 |
| Return on Equity (ROE) | -0.67 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 3.40 |
| Current Ratio | 3.40 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 424.82 |
| Assets | 468.30 |
| Liabilities | 341.50 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 100.56 |
| Operating Income | -142.79 |
| Net Income | -119.05 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -229.91 |
| Cash from Investing | 107.13 |
| Cash from Financing | 81.54 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | BlackRock, Inc. | 6.20 | -24.19 | |
| 13G | Ra Capital Management, L.p. | 9.90 | ||
| 13G/A | Polaris Venture Partners VI, L.P. | 10.20 | -9.09 | |
| 13G/A | Morgan Stanley | 4.50 | -5.94 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 142,720 | 451,054 | 31.64 | |
| 179,288 | 556,706 | 32.21 | |
| 123,532 | 981,810 | 12.58 | |
| 143,879 | 432,838 | 33.24 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ADPT – Adaptive Biotechnologies Corporation | AGIO – Agios Pharmaceuticals, Inc. |
| AKRO – Akero Therapeutics, Inc. | ALKS – Alkermes plc |
| ALLK – Allakos Inc. |
Financial data and stock pages provided by
Fintel.io